US EditionPharmaceutical industry criticizes the drug pricing plan Trump says he’ll sign
- On Monday, President Donald Trump issued an executive order intended to reduce the prices of certain drugs covered by Medicare through a "most favored nation" pricing strategy.
- Trump previously tried this policy during his first term, aiming to tie U.S. Medicare drug prices to the lowest prices paid internationally, but a court blocked that attempt.
- The order focuses on medications administered during doctor's visits that are covered under Medicare, such as costly cancer treatments and injectable drugs, potentially saving the government billions, though most individuals are unlikely to experience lower prices.
- Pharmaceutical industry leaders like PhRMA CEO Stephen J. Ubl criticized the policy as a 'bad deal' that risks billions in domestic research investment and increases U.S. Reliance on foreign innovation.
- The policy renews debate over high U.S. Drug prices, signaling possible federal efforts to contain costs amid ongoing political and legal challenges.
Insights by Ground AI
Does this summary seem wrong?
87 Articles
87 Articles
All
Left
17
Center
13
Right
14
Breitbart Business Digest: Trump's MFN Drug Price Plan and the Trade War in Pharma Lab Coats
For decades, American consumers have been paying the world’s highest drug prices—not because we use more medicine, or demand higher quality, but because our government chose not to negotiate. The post Breitbart Business Digest: Trump’s MFN Drug Price Plan and the Trade War in Pharma Lab Coats appeared first on Breitbart.
·United States
Read Full Article
Coverage Details
Total News Sources87
Leaning Left17Leaning Right14Center13Last UpdatedBias Distribution39% Left
Bias Distribution
- 39% of the sources lean Left
39% Left
L 39%
C 30%
R 32%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
